FDA Approves Nerlynx for HER2+ MBC

Options

FDA Approves Nerlynx for HER2-Positive Metastatic Breast Cancer
March 4, 2020

On Feb. 25, 2020, the FDA approved Nerlynx (chemical name: neratinib) in combination with Xeloda (chemical name: capecitabine) to treat advanced or metastatic HER2-positive breast cancer that has been treated with two or more anti-HER2 therapies. Read more...

Categories